Abstract 523P
Background
Chemo-immunotherapy is the standard first-line (1L) therapy for patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). However, not all ES-SCLC pts benefit from chemo-immunotherapy. We aimed to assess the efficacy and safety of camrelizumab + apatinib as maintenance treatment for ES-SCLC pts who had disease control after standard 1L chemotherapy.
Methods
Key inclusion criteria were age 18-75 years, histologically or cytologically confirmed ES-SCLC, ECOG PS 0-1, no disease progression after 4∼6 cycles of standard 1L chemotherapy. Eligible pts received camrelizumab (200mg, iv, d1, q3w) + apatinib (250mg, po, qd) until disease progression or intolerable toxicity. The primary endpoint was progression free survival (PFS); key secondary endpoints included overall response rate (ORR), disease control rate (DCR) and safety.
Results
From July 2021 to July 2023, 18 pts who received at least 1 dose of camrelizumab + apatinib were analyzed. The median age was 59 years (range: 45-75) with 16 (88.9%) males, 11 (61.1%) former smokers, 4 (22.2%) current smokers and 13 (72.2%) with ECOG PS 1. One patient (5.6%) had brain metastasis, 3 (16.7%) had liver metastasis, and 4 (22.2%) had bone metastasis. At data cutoff, 5 pts remained on treatment, and 16 pts had at least 1 post-treatment tumor assessment. The median PFS was 6.4 months (3.0-NR), the confirmed ORR and DCR were 12.5% (2/16) and 100% (16/16), respectively. Treatment-related adverse events (TRAEs) were reported in 17 pts (94.4%). Among them, 10 (55.6%) pts experienced grade 3 or 4 TRAEs. This included 2 pts (11.1%) with diarrhea, 2 (11.1%) with hyperglycemia, and 1 patient each (5.6%) with increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocyte count, pancreatitis, hyponatremia, asthenia, elevated γ-glutamyl transferase and nerve injury. No grade 5 adverse events occurred.
Conclusions
Camrelizumab plus apatinib had promising efficacy and acceptable safety as maintenance treatment in ES-SCLC pts who responded or had stable disease after standard 1L chemotherapy. Further validation is warranted.
Clinical trial identification
NCT04901754.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract